Regeneron Pharmaceuticals is under investigation by Pomerantz LLP following disappointing Phase 3 trial results for its melanoma treatment, which failed to show significant improvement over existing therapy. The news led to a nearly 10% drop in Regeneron's stock price. The investigation will examine whether Regeneron and its executives engaged in securities fraud or other unlawful practices. Investors affected may consider joining the class action lawsuit as the case develops.
The European Medicines Agency (EMA) has accepted Regeneron Pharmaceuticals' Marketing Authorization Application for Otarmeni (lunsotogene parvec), a gene therapy targeting biallelic OTOF variant-associated hearing loss, for accelerated assessment. Ot...
Regeneron's Lynozyfic (linvoseltamab) monotherapy achieved a 100% hematologic complete response in patients with second-line-plus systemic amyloid light chain (AL) amyloidosis in the Phase 1/2 LINKER-AL2 trial. The drug normalized free light chains b...
